Novartis’s big wager on RNAi approaches the finish line
The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
Go or no go? Big decisions loom for Bristol and Sanofi
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Fourth-quarter events to watch for big pharma
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Amgen and Astra hope to carve out a place in asthma
Pivotal data are expected soon on tezepelumab, Amgen and Astrazeneca's shot at non-eosinophilic asthma.
Go or no go? A quiet month ahead for US approval verdicts
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
